Drugs / GamFluVac
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03651544 | Oct → Dec 2018 | avian influenza | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04034290 | Oct 2019 → Jun 2020 | — | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GamFluVac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03651544 ↗ |
| Modality | Vaccine | “GamFluVac Vector Vaccine” NCT03651544 ↗ |
| Route | Intranasal | “administrated by intranasal drip” NCT04034290 ↗ |